Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31555925 | 1.00 | KDM4E (0.52) | KDM4ERECQLALDH1A1MEN1KMT2A | |
| SCHEMBL6686436 | 1.00 | KDM4E (0.52) | KDM4ERECQLALDH1A1MEN1KMT2A | |
| SCHEMBL30062272 | 1.00 | KDM4E (0.52) | KDM4ERECQLALDH1A1MEN1KMT2A | |
| SCHEMBL1507545 | 1.00 | KDM4E (0.52) | KDM4ERECQLALDH1A1MEN1KMT2A | |
| SCHEMBL44670 | 0.97 | KDM4E (0.55) | KDM4ERECQLALDH1A1MEN1KMT2A | |
| SCHEMBL18879745 | 0.94 | KDM4E (0.57) | KDM4ERECQLALDH1A1MEN1KMT2A | |
| SCHEMBL1133540 | 0.94 | KDM4E (0.52) | KDM4ERECQLALDH1A1MEN1KMT2A | |
| SCHEMBL24508502 | 0.90 | KDM4E (0.50) | KDM4ERECQLALDH1A1MEN1KMT2A | |
| SCHEMBL17992469 | 0.90 | KDM4E (0.50) | KDM4ERECQLALDH1A1MEN1KMT2A | |
| SCHEMBL19478680 | 0.90 | KDM4E (0.50) | KDM4ERECQLALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702004-A1 | NONIONIC SURFACTANTS | Detect, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20240360076-A1 | NONIONIC SURFACTANTS | DETECT INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240173421-A1 | MODULATION OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY | SEAGEN INC. | 2024-05-30 | — | — | US | disclosed |
| CN-118001423-A | Hydrophilic anti-Nectin-4 antibody coupled drug as well as preparation method and application thereof | 杭州爱科瑞思生物医药有限公司 | 2024-05-10 | — | — | CN | disclosed |
| EP-4326333-A1 | MODULATION OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY | Seagen Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-117597150-A | Modulation of antibody dependent cellular cytotoxicity | 思进公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2023-12-14 | — | — | US | disclosed |
| EP-4084829-A1 | OXAZINE-BASED WATER-SOLUBLE FLUOROPHORE COMPOUNDS FOR IN VIVO NERVE IMAGING | Oregon Health & Science University (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-2001849-B1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-11-26 | — | — | EP | disclosed |
| EP-2468727-A1 | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | F. Hoffmann-La Roche AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-8183262-B2 | Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine | HOFFMANN-LA ROCHE INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-7642264-B2 | Phenyl-substituted pyrimidine derivatives as mGluR antagonists | HOFFMAN-LA ROCHE INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090318474-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS | GATTI MCARTHUR SILVIA | 2009-12-24 | — | — | US | disclosed |
| EP-2001849-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007110337-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-04 | — | — | WO | disclosed |
| US-20070060497-A1 | Reagents for modifying biopharmaceuticals, the use and production thereof | CELARES GMBH (DE) | 2007-03-15 | — | — | US | disclosed |
| US-20070060497-A1 | Reagents for modifying biopharmaceuticals, the use and production thereof | CELARES GMBH (DE) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | P2RX2, P2RY2, P2RX1 | KDM4E 2568/4885RECQL 355/4885ALDH1A1 1138/4885 |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | KDM4E 1725/4885RECQL 83/4885ALDH1A1 641/4885 |
| US-20090318474-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS | GRM2, GRM1, GRM3 | KDM4E 1276/4885RECQL 1091/4885ALDH1A1 3286/4885 |
| US-20240360076-A1 | NONIONIC SURFACTANTS | POLL, POLRMT, POLI | KDM4E 4782/4885RECQL 991/4885ALDH1A1 4251/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | KDM4E 1725/4885RECQL 83/4885ALDH1A1 641/4885 |
| US-20240173421-A1 | MODULATION OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY | CD47, CD2, SSB | KDM4E 3130/4885RECQL 3929/4885ALDH1A1 2766/4885 |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | KDM4E 1725/4885RECQL 83/4885ALDH1A1 641/4885 |
| US-20070060497-A1 | Reagents for modifying biopharmaceuticals, the use and production thereof | KIT, PIGS, CMA1 | KDM4E 1143/4885RECQL 2250/4885ALDH1A1 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.